Financial Review (All amounts are in Canadian dollars)
------------------------------------------------------
The consolidated loss for the year ended December 31, 2007 was $6,316,000 or $(0.26) per share compared with a loss of $5,949,000 or $(0.27) per share for the year ended December 31, 2006, an increase of $367,000.
Total product sales of PREVU(x) Skin Cholesterol tests amounted to $41,000 in 2007 compared with $7,000 in 2006. License revenue was $53,000 in 2007 compared to $3,329,000 in 2006, a decrease of $3,276,000. License revenue consists primarily of the upfront cash payments received in accordance with the respective licensing agreements, which have been deferred and recognized into income on a straight-line basis over the terms of the agreements. For 2007, the license revenue represents the amortization of the $533,000 (US$500,000) received upon signing of the license agreement with AstraZeneca on July 13, 2007.
Research and development expenses for the year decreased by $1,996,000
to $2,778,000 from $4,774,000 in 2006. The variance for the year reflects:
- A decrease of $2,224,000 in spending on clinical trials for skin
cholesterol and cancer to $347,000 from $2,571,000 in 2006, following
the submission of the US FDA application;
- An decrease of $103,000 in product liability insurance due which is
related to the reduced number of clinical trials undertaken in 2007;
- An increase of $175,000 in performance-based compensation expense
resulting from achievement of milestones;
- An increase of $88,000 in product development and subcontract
research as related to the vali
'/>"/>
| SOURCE PreMD Inc. Copyright©2008 PR Newswire. All rights reserved |